Inflammation in COPD: Implications for Management

被引:125
作者
Sethi, Sanjay [1 ]
Mahler, Donald A. [2 ]
Marcus, Philip [3 ]
Owen, Caroline A. [4 ,5 ]
Yawn, Barbara [6 ]
Rennard, Stephen [7 ]
机构
[1] SUNY Buffalo, VA Med Res 151, Buffalo, NY 14215 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[3] St Francis Hosp, Roslyn, NY USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] Olmsted Med Ctr, Rochester, MN USA
[7] Univ Nebraska, Med Ctr, Omaha, NE USA
关键词
Anti-inflammatory; COPD; Exacerbation; Inflammation; OBSTRUCTIVE PULMONARY-DISEASE; BRONCHIAL EPITHELIAL-CELLS; AIR-FLOW LIMITATION; INHALED CORTICOSTEROIDS; LUNG-FUNCTION; SALMETEROL/FLUTICASONE PROPIONATE; ANTIINFLAMMATORY ACTIVITY; FLUTICASONE PROPIONATE; ACUTE EXACERBATION; SMOKING-CESSATION;
D O I
10.1016/j.amjmed.2012.06.024
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Chronic obstructive pulmonary disease (COPD) is recognized by the Global Initiative for Chronic Obstructive Lung Disease guidelines as an inflammatory disease state, and treatment rationales are provided accordingly. However, not all physicians follow or are even aware of these guidelines. Research has shown that COPD inflammation involves multiple inflammatory cells and mediators and the underlying pathology differs from asthma inflammation. For these reasons, therapeutic agents that are effective in asthma patients may not be optimal in COPD patients. COPD exacerbations are intensified inflammatory events compared with stable COPD. The clinical and systemic consequences believed to result from the chronic inflammation observed in COPD suggest that inflammation intensity is a key factor in COPD and exacerbation severity and frequency. Although inhaled corticosteroids are commonly used and are essential in asthma management, their efficacy in COPD is limited, with only a modest effect at reducing exacerbations. The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents. (C) 2012 Elsevier Inc. All rights reserved. circle The American Journal of Medicine (2012) 125, 1162-1170
引用
收藏
页码:1162 / 1170
页数:9
相关论文
共 93 条
[1]
Adcock IM, 2010, CURR PHARM DESIGN, V16, P3554
[2]
[Anonymous], GLOB BURD DIS 2004 U
[3]
[Anonymous], INT J CHRON OBSTRUCT
[4]
Impact of exacerbations on COPD [J].
Anzueto, A. .
EUROPEAN RESPIRATORY REVIEW, 2010, 19 (116) :113-118
[5]
Asano Kazuhito, 2008, Int J Chron Obstruct Pulmon Dis, V3, P781
[6]
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease [J].
Barnes, NC ;
Qiu, YS ;
Pavord, ID ;
Parker, D ;
Davis, PA ;
Zhu, L ;
Johnson, M ;
Thomson, NC ;
Jeffery, PK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (07) :736-743
[7]
Immunology of asthma and chronic obstructive pulmonary disease [J].
Barnes, Peter J. .
NATURE REVIEWS IMMUNOLOGY, 2008, 8 (03) :183-192
[8]
New Therapies for Chronic Obstructive Pulmonary Disease [J].
Barnes, Peter J. .
MEDICAL PRINCIPLES AND PRACTICE, 2010, 19 (05) :330-338
[9]
Inhaled Corticosteroids in COPD: A Controversy [J].
Barnes, Peter J. .
RESPIRATION, 2010, 80 (02) :89-95
[10]
Emerging Pharmacotherapies for COPD [J].
Barnes, Peter J. .
CHEST, 2008, 134 (06) :1278-1286